.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Accenture
UBS
McKinsey
AstraZeneca
Chubb
Novartis
Mallinckrodt
Cerilliant
Farmers Insurance

Generated: December 13, 2017

DrugPatentWatch Database Preview

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for abacavir sulfate; lamivudine; zidovudine and what is the scope of abacavir sulfate; lamivudine; zidovudine patent protection?

Abacavir sulfate; lamivudine; zidovudine
is the generic ingredient in two branded drugs marketed by Lupin Ltd and Viiv Hlthcare, and is included in two NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Abacavir sulfate; lamivudine; zidovudine has one hundred and eighty patent family members in fifty-seven countries and fifteen supplementary protection certificates in ten countries.

There are eleven drug master file entries for abacavir sulfate; lamivudine; zidovudine. Four suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

Tentative approvals for ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

Applicant Application No. Strength Dosage Form
u► SubscribeEQ 300MG BASE; 150MG; 300MGTABLET; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Lupin LtdABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINEabacavir sulfate; lamivudine; zidovudineTABLET;ORAL202912-001Dec 5, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: abacavir sulfate; lamivudine; zidovudine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000► Subscribe► Subscribe
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000► Subscribe► Subscribe
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000► Subscribe► Subscribe
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000► Subscribe► Subscribe
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000► Subscribe► Subscribe
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000► Subscribe► Subscribe
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000► Subscribe► Subscribe
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000► Subscribe► Subscribe
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000► Subscribe► Subscribe
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: abacavir sulfate; lamivudine; zidovudine

Country Document Number Estimated Expiration
Australia1881092► Subscribe
Argentina059120► Subscribe
Portugal983271► Subscribe
Brazil9809127► Subscribe
Brazil9607851► Subscribe
Singapore52455► Subscribe
South Africa9204007► Subscribe
Taiwan254939► Subscribe
Iceland3873► Subscribe
Denmark0817637► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB05/027United Kingdom► SubscribeSPC/GB05/027: 20050922, EXPIRES: 20191216
99C0033Belgium► SubscribePRODUCT NAME: ABACAVIR SULFATE; NATL. REGISTRATION NO/DATE: EU/1/99/112/001 19990708; FIRST REGISTRATION: CH 55048 19990628
00195Netherlands► SubscribePRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDB AAR ZUURADDITIEZOUT, IN HET BIJZONDER HET HEMISULFAAT, EN LAMIV UDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT; REGISTRTION NO/DATE: EU/04/298/001-002 20041217
0817637/01Switzerland► SubscribePRODUCT NAME: ABACAVIR + LAMIVUDIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 56977 31.10.2005
C0022France► SubscribePRODUCT NAME: ABACAVIR SULFATE; LAMIVUDINE; REGISTRATION NO/DATE: EU/1/04/298/001 20041217
0028Netherlands► SubscribePRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBAAR ESTER, IN HET BIJZONDER ABACAVIR SULFAAT; REGISTRATION NO/DATE: EU/1/99/112/001-002 19990708
C/GB99/032United Kingdom► SubscribePRODUCT NAME: ABACAVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR DERIVATIVE INCLUDING ABACAVIR SULPHATE; REGISTERED: CH CH 55048 001 19990628; CH CH 55049 002 19990628; UK EU/1/99/112/001 19990708; UK EU/1/99/112/002 19990708
C016/2005Ireland► SubscribeSPC016/2005: 20060407, EXPIRES: 20191216
2005 00028Denmark► Subscribe
/1999Austria► SubscribePRODUCT NAME: ''ABACAVIR'', GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER DERIVATS, EINSCHLIESSLICH ABACAVIR-SULFAT.; NAT. REGISTRATION NO/DATE: EU/1/99/112/001 EU/1/99/112/002 19990708; FIRST REGISTRATION: LI 55048 001, 55049 002 19990628
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Fish and Richardson
Johnson and Johnson
US Army
McKinsey
Deloitte
Fuji
Covington
US Department of Justice
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot